Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
Epidemiologist Elizabeth A. Platz explains what goes into calculating cancer risk estimates, such as rate ratio, hazard ratio, and...
At AACR IO 2026, Nobel laureate Fred Ramsdell explained the research history of regulatory T cells (Tregs) and the...
In February, the editors of AACR's journals highlighted studies on the FDA’s accelerated approval pathway, how metabolism impacts prostate...
Elizabeth M. Jaffee and Philip D. Greenberg opened AACR IO 2026 with a look at cancer vaccines and the...
Colorectal cancer cases are becoming more common in younger adults, but there are now more options for screening beyond...
Researchers and a patient advocate weighed in on current and emerging treatment options for each stage of triple-negative breast...
Twenty early-career cancer researchers from around the world were selected for the 2026 AACR Global Scholar-in-Training Award (GSITA) programs.
Researchers are working on multiple innovative approaches to cancer vaccines, including nanoparticle delivery, a universal booster, and more.
Elizabeth M. Jaffee and Antoni Ribas will look to feature the next wave of immuno-oncology advances as Cancer Immunology Research's...
The AACR, The Mark Foundation, Lustgarten Foundation, Break Through Cancer, and Tina’s Wish will explore early detection approaches for...